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infarction, stroke and angina were estimated to be CAD20,372,
CAD36,356 and CAD3,480, respectively. Costs in subsequent
years were CAD1304, CAD9587 and CAD1623, respectively.
Congestive heart failure costs were estimated to be CAD2232.
First year costs of end-stage renal disease (ESRD) ranged
between CAD53,046 and CAD 95,550 depending on the type of
dialysis. In subsequent years, ESRD costs were in the range
CAD31,356 to 147,225. Major costs associated with neuropa-
thy and foot ulcer complications included CAD1,140 for 
uninfected foot ulcer, CAD2,387 for infected ulcer, CAD8,529
for treatment of gangrene and CAD26,875 for amputation.
CONCLUSIONS: Cost data are available in Canada, but no
published data were identiﬁed for Australia. These data are of
central importance to modeling groups to allow the simulation
of the long-term costs associated with diabetes and its compli-
cations, as well as the cost-effectiveness of treatments for this
disease.
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PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL
ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN
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OBJECTIVE: To evaluate the annual direct pharmacy costs-
per-patient for reaching the goal of an A1C of < 7.0% and
£6.5% among patients with type-2 diabetes using oral antidia-
betic agents (OADs) and either biphasic insulin aspart 70/30
(BIAsp 70/30) or glargine. METHODS: Data from a recent clin-
ical study (INITIATE) demonstrated that over a 28-week period,
signiﬁcantly more insulin-naïve, type-2 subjects previously
treated with OADs reached the American Diabetes Association
target of A1C <7.0% with twice-daily BIAsp 70/30 + metformin
(met) ± thiazolidinedione (TZD) compared to bedtime insulin
glargine + met ±TZD (66% vs. 40%; p = 0.0002). Likewise, a
statistically signiﬁcant difference favoring BIAsp 70/30 was
observed when assessing the two cohorts against the Interna-
tional Diabetes Federation target of A1C £6.5% (42% vs. 28%;
p = 0.0356). The annual direct pharmacy costs for the insulins,
metformin, and TZD (pioglitazone) were calculated using pub-
lished AWP cost data within the US. RESULTS: Cost calculations
were based on end-of-study mean daily medication doses of 0.82
IU/kg BIAsp 70/30 (mean weight: 95.7kg), 0.55IU/kg glargine
(mean weight: 93.8kg), 1500mg metformin, and 30mg piogli-
tazone for subjects treated with TZD (32% in each arm). The
mean costs-per-patient reaching A1C values of <7.0% were
$5295 with BIAsp 70/30 and $6850 with glargine, and $8321
and $9786, respectively, for subjects reaching £6.5%. CON-
CLUSION: The mean annual direct pharmacy costs-per-patient
were considerably lower using BIAsp 70/30 compared to
glargine, indicating that BIAsp 70/30 is a better investment of
health care dollars when aiming to bring type-2 patients to better
control at clinically endorsed A1C targets.
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The prevalence and cost of type-2 diabetes is signiﬁcant in elderly
patients. Improved glycemic control may be associated with
better health outcomes and lower cost. OBJECTIVE: To analyze
health care resource use and estimate cost of care over a two-
year period in elderly patients (>60 years) with type-2 diabetes
receiving treatment with rosiglitazone (RSG) plus sub-maximal
sulfonylurea (SU) combination therapy (n = 115) or progressive
uptitration of the SU, glipizide (GLIP), (n = 110) in the Rosigli-
tazone Early vs. Sulfonylurea Titration (RESULT) clinical trial.
METHODS: Treatment was individualized, targeting ADA
deﬁned goals, as appropriate, with uptitration required for FPG
>180mg/dL to a max of glipizide 20mg bid and RSG 4mg bid.
Patient self-reported hospitalizations, emergency room (ER)
visits, and physician visits were prospectively collected for the
duration of the trial. Health care utilization rates were reported
and analyzed as rates per 1000 patient-days using Poisson regres-
sion models. National average unit costs were applied to esti-
mate total direct medical cost, where appropriate costs were
adjusted for the duration of therapy and expressed as cost per
patient per month (PPPM). RESULTS: By the end of two years,
disease progression (time to reach conﬁrmed FPG ≥ d 180mg/dl)
was observed in only two patients (1.7%) randomized to RSG +
GLIP, compared to 27 patients (24.3%) taking GLIP alone (p <
0.0001). In comparison with patients in the GLIP group, patients
in the RSG + GLIP group had signiﬁcantly fewer ER visits (p =
0.0006) and hospitalizations (p = 0.0263). There were no sta-
tistically signiﬁcant differences in unscheduled physician ofﬁce
visits between the two treatment groups. Average PPPM costs
were signiﬁcantly lower for the RSG + GLIP group ($480) 
compared to the GLIP monotherapy group ($644) (p < 0.05).
CONCLUSION: The addition of RSG to SU therapy was asso-
ciated with a decreased use of medical resources, in particular
hospitalizations and ER visits, and resulted in signiﬁcant cost
savings.
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OBJECTIVES: A clinical trial showed that intensive therapy with
the rapid-acting insulin analogue insulin aspart (IAsp) was supe-
rior to soluble human insulin (SHI), both combined with NPH
insulin as basal insulin, with respect to improving glycaemic
control (baseline-adjusted difference in HbA1c of -0.12%, p <
0.02). We investigated how this small but signiﬁcant difference,
together with other clinical parameters, would affect the long-
term complications associated with diabetes, health care costs
and cost-effectiveness in the UK setting. METHODS: The pub-
lished and validated CORE Diabetes Model was used to predict
long-term complications, improvements in life years gained
(LYG), quality-adjusted life years (QALYs) gained, long-term
costs and cost-effectiveness for IAsp versus SHI. Standard
Markov/Monte Carlo simulation techniques were used to
describe the incidence and progression of complications. Proba-
bilities of complications and HbA1c-dependent adjustments were
derived from the DCCT, other major clinical trials and popula-
tion-based studies. Clinical inputs were taken from a six-month
multinational, open-label, parallel-group trial in type-1 diabetes
patients. Costs of treating complications in the UK (inﬂated to
2004 costs) and utility values were obtained from published
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sources. Direct costs of diabetes complications and drug treat-
ment were projected over patients’ lifetimes from a UK National
Health Service perspective. Both costs and QALYs were dis-
counted at 3.5% p.a. Sensitivity analyses were performed.
RESULTS: The model projected that treatment with IAsp would
result in an additional 0.08 LYG and 0.09 QALYs per patient.
Total lifetime costs/patient were estimated to increase by £419.
The cost/LYG was calculated to be £5430 and cost/QALY
£4825. CONCLUSION: The model predicted that treatment
with insulin aspart would result in long-term improvements in
health outcomes and quality of life compared to soluble human
insulin in patients with type-1 diabetes. The cost-effectiveness
result is well within the range considered to represent good value
for money in the UK.
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OBJECTIVE: In their evaluation of the cost effectiveness of
insulin glargine, NICE included an assumption that switching to
insulin would result in decreased health utility (8%). This altered
notably any resulting cost-utility ratios. The purpose of this
study was to test this hypothesis. METHODS: The design was
a before-and-after study for type-2 patients who required switch-
ing to insulin. All followed an algorithm to achieve fasting and
post-prandial blood glucose targets. Outcome measures included
a measure of utilit (EQ5Dindex) at baseline, three-months and six-
months. This report was a preliminary analysis of the ﬁrst 48
subjects, of which 32 had completed 12 weeks and 26 had com-
pleted the full 24-week study. RESULTS: Of the 26 subjects, 21
(81%) remained on glargine with or without OHAs, two
required additional pre-meal boluses, and three required twice-
daily pre-mixtures. The mean (SD) EQ5Dindex at baseline was
0.655 (0.275; n = 24), at three-months 0.637 (0.333; D vs. base-
line NS) and at six-months 0.710 (0.319; D vs. baseline NS). At
three-months, six patients had worse utility and six better utility,
while 12 reported no change. At six-months, four patients had
worse utility after switching, and 11 had better utility, the
remaining nine subjects reported no change. Over the six-
months, mean BMI increased from 29.4 to 30.0kg/m2 (n = 23,
p < 0.001) and mean HbA1c decreased from 10.1% to 7.8% (n
= 23, p < 0.001). Mean daily insulin dose at six-months was 61.6
units (range 24 to 178). CONCLUSIONS: This is a limited but
important interim analysis. The hypothesis that switching to
insulin–here insulin glargine—resulted in a notable decrease in
utility (quality of life) was rejected, with a trend for a clinically
meaningful improvement in utility. Economic evaluations
should, therefore, exclude this assumption. This observation is
not necessarily generalisable to all insulin regimens.
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OBJECTIVES: To evaluate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in
patients with type-2 diabetes. METHODS: Retrospective analy-
sis of a state Medicaid claims data was conducted in patients
with type-2 diabetes identiﬁed using ICD-9 diagnosis codes
(250.0¥–250.9¥, where x = 0 or two) in the year 2001. Patients
≥65 years or those with managed care coverage were excluded.
Presence of cardiovascular co-morbidity in the year 2001 was
identiﬁed using appropriate ICD-9 codes. Semi-logarithmic OLS
models were used to estimate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in year
2002, controlling for demographic characteristics (age, gender,
race, and urban/rural location), presence of peripheral vascular
conditions, cerebrovascular conditions, hypertension, hyperlipi-
demia, and other co-morbid conditions. Two-part models were
used for estimating the impact of cardiovascular co-morbidity on
speciﬁc costs such as ER/hospitalization, outpatient and pre-
scription. Smearing estimates were used to interpret the results
from the semi-logarithmic models. RESULTS: Presence of car-
diovascular co-morbidity had a signiﬁcant impact on all cate-
gories of total and diabetes-related health care costs, except
diabetes-related prescription drug costs. Type-2 diabetes patients
with cardiovascular co-morbidity had signiﬁcantly higher 
total health care costs (38.9%, $12,550 vs. $9,031), ER/
hospitalization costs (239.8%, $4,845 vs. $1,426), outpatient
costs (35.3%, $3,956 vs. $2,925) and prescription drug costs
(15.1%, $4,686 vs. $4,071) compared to those without cardio-
vascular co-morbidity. Similarly, type-2 diabetes patients with
cardiovascular co-morbidity had signiﬁcantly higher diabetes-
related total health care costs (59.7%, $4349 vs. $2724),
ER/hospitalization costs (346.8%, $1911 vs. $428) and outpa-
tient costs (17.4%, $740 vs. $631) compared to patients without
cardiovascular co-morbidity. CONCLUSIONS: Presence of car-
diovascular co-morbidity in patients with type-2 diabetes signif-
icantly increases total and diabetes-related health care costs, with
ER/hospitalization costs accounting for the highest percentage
increase.
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OBJECTIVE: To examine the impact of pre-existing depression
on utilization patterns and adherence to oral hypoglycemic
agents (OHAs) in patients newly diagnosed with type-2 diabetes.
METHODS: Newly diagnosed type-2 diabetes patients during
the three-year period (1998–2000) were identiﬁed from a Med-
icaid claims database. Presence of pre-existing depression was
determined on the basis of ICD-9 CM codes for depression. 
Utilization patterns (switching, augmentation) and adherence to
OHAs were computed for a 12-month follow up period from the
date of the index OHA prescription. A multivariate framework
was used to estimate the impact of depression on utilization pat-
terns and adherence, controlling for confounders such as demo-
graphics, co-morbidity, diabetes severity, regimen complexity,
and interaction with health care providers. RESULTS: A total of
1326 newly diagnosed type-2 diabetes patients were identiﬁed
(depressed = 471; non-depressed = 855). A signiﬁcantly higher
number of depressed patients (23.3%) switched or augmented
therapy as compared to non-depressed patients (16.2%). Results
of a multinomial logit model indicated that controlling for
covariates, patients with depression were 1.7 times more likely
to switch (p = 0.046) and two times more likely to augment
